Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase NA 7Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 73Thoracic 17Breast 16Gynecologic 13Head & Neck 11Genitourinary 11Dermatologic 7Sarcoma 6CNS 5Endocrine 2NET 1Lymphoid 1

Conditions

Neuroendocrine Tumors 60Breast Neoplasms 22Thyroid Neoplasms 20Neoplasms 20Multiple Endocrine Neoplasia Type 1 20Carcinoma, Renal Cell 20Melanoma 19Carcinoma, Non-Small-Cell Lung 19Adrenocortical Carcinoma 19Small Cell Lung Carcinoma 17Thyroid Cancer, Papillary 16Colorectal Neoplasms 16Thyroid Carcinoma, Anaplastic 15Carcinoma, Neuroendocrine 15Carcinoma, Medullary 14Prostatic Neoplasms 13Pheochromocytoma 13Pancreatic Neoplasms 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Carcinoid Tumor 13Insulinoma 12Uterine Cervical Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Head and Neck Neoplasms 11Adenocarcinoma, Follicular 11Salivary Gland Neoplasms 10Pituitary Neoplasms 10Colonic Neoplasms 10

Interventions

Cytoreduction Surgical Procedures 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Neoplasms × Endocrine × Clear all
NCT03411915 2022-05-10

DUET-1

Xencor, Inc.

Phase 1 Completed
62 enrolled
EndocrineGastrointestinalNET

Gastrointestinal Neoplasms, Neuroendocrine Tumors

NCT00436657 2012-04-02

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
10 enrolled
CNSEndocrineGastrointestinalGenitourinaryGynecologicSarcoma

Adenocarcinoma, Gastrointestinal Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Peritoneal Neoplasms, Retroperitoneal Neoplasms, Rhabdomyosarcoma, Sarcoma, Adrenocortical Carcinoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡